Neurocrine Biosciences (NBIX) 16.39 $NBIX
Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
PR Newswire - Wed Sep 03, 12:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Morgan Stanley Global Healthcare Conference in New York City.
The Best Hedge Fund You've Never Heard Of and Its Top 5 Stock Picks
at The Street - Tue Aug 26, 1:22PM CDT
It's not the hedge fund mogul you expect.
Neurocrine Biosciences posts higher net loss of USD13.4m for Q2 2014
M2 - Thu Aug 07, 5:02AM CDT
Drug company Neurocrine Biosciences (NasdaqGS:NBIX) disclosed on Wednesday that its net loss was USD13.4m (USD0.18 loss per share) for the second quarter ended 30 June 2014.
Neurocrine Biosciences Reports Second Quarter 2014 Results
PR Newswire - Wed Aug 06, 3:02PM CDT
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended June 30, 2014. For the second quarter of 2014, the Company reported a net loss of $13.4 million, or $0.18 loss per share, compared to a net loss of $12.2 million, or $0.18 loss per share, for the same period in 2013. For the six months ended June 30, 2014, the Company reported a net loss of $25.2 million, or $0.35 loss per share, as compared to net loss of $24.3 million, or $0.36 loss per share, for the first half of last year.
Global PCOS (Stein-Leventhal Syndrome) Drugs Market 2014-2018
M2 - Wed Aug 06, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gszg6d/global_pcos_drugs) has announced the addition of the "Global PCOS Drugs Market 2014-2018" report to their offering. The analysts forecast the Global PCOS Drugs market will grow at a CAGR of 2.665% over the period 2013-2018. PCOS, also known as Stein-Leventhal Syndrome, is one of the most common hormonal endocrine disorders in women. It is characterized by polycystic ovaries, irregular or no menstrual periods, irregular ovulation, and high levels of androgens (male hormones) in the body. The exact cause of PCOS is unknown. In PCOS, small cysts form on the ovaries, which do not produce a sufficient amount of hormone to initiate ovulation. The ovarian follicles, which are filled with fluid in preparation for ovulation, remain as cysts when ovulation does not occur. Lifestyle modifications, medication, and surgery are some of the currently available treatments for PCOS. This report covers the present scenario and the growth prospects of the Global PCOS Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through the sales of marketed, off-label, and generic drugs used in the treatment of PCOS. The report, the Global PCOS Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global PCOS Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Bristol Myers Squibb Co. - Merck & Co. Inc. - Novartis AG - Sanofi SA - Teva Pharmaceutical Inc. Other Prominent Vendors - AstraZeneca plc - Catalysis SL - Crinetics Pharmaceuticals Inc. - Dexa Medica Group - EffRx Inc. - Neurocrine Biosciences Inc. Market Drivers/Challenges/Trends - Increase in Patient Population. - Lack of Approved Drugs. - Increase in Awareness of PCOS Drugs. Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. For more information visit http://www.researchandmarkets.com/research/gs...pcos_drugs
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences
PR Newswire - Thu Jul 31, 7:40AM CDT
On Wednesday, July 30, 2014, the NASDAQ Composite ended at 4,462.90, up 0.45%, the Dow Jones Industrial Average finished the day 0.19% lower at 16,880.36, and the S&P 500 closed at 1,970.07, up 0.01%. During the session five out of ten sectors ended in positive. The S&P 500 Health Care Sector Index ended the day at 718.94, up 0.36%, and the index has advanced 2.05% in the last one month. Investor-Edge has initiated coverage on the following equities: IsoRay Inc. (NYSE MKT: ISR), Neurocrine Biosciences Inc. (NASDAQ: NBIX), OPKO Health Inc. (NYSE: OPK), Orexigen Therapeutics Inc. (NASDAQ: OREX), and Gilead Sciences Inc. (NASDAQ: GILD). Free research on these five companies can be accessed at:
Critical Alerts For Silicon Motion Technology, Pharmacyclics, 3D Systems, Walgreen, and Neurocrine Biosciences Released By InvestorsObserver
PR Newswire - Wed Jul 30, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SIMO, PCYC, DDD, WAG, and NBIX.
Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results
PR Newswire - Tue Jul 29, 9:00AM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its second quarter 2014 financial results after the Nasdaq market closes on Wednesday, August 6, 2014. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Thursday morning, August 7, 2014 at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time).
Global Insomnia Clinical Trials Review, H2, 2014 Featuring 10 Companies & 10 Institutes
M2 - Thu Jul 17, 8:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xplssq/insomnia_global) has announced the addition of the "Insomnia Global Clinical Trials Review, H2, 2014" report to their offering. Insomnia Global Clinical Trials Review, H2, 2014" provides data on the Insomnia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Insomnia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Insomnia. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Takeda Pharmaceutical Company Limited - Merck & Co., Inc. - Dainippon Sumitomo Pharma Co., Ltd. - Sanofi - Neurocrine Biosciences, Inc. - Pfizer Inc. - GlaxoSmithKline plc - Neurim Pharmaceuticals Ltd - Eisai Co., Ltd. - Actelion Ltd Clinical Trial Overview of Top Institutes / Government - University of Rochester - Duke University - U.S. Department of Veterans Affairs - Karolinska Institute - University of Pittsburgh - Brigham and Women's Hospital - Stanford University - The University of Hong Kong - Massachusetts General Hospital - National Institute of Mental Health For more information visit http://www.researchandmarkets.com/research/xp...nia_global
Women Health Market Growth Prospects for 2014 to 2018 Analyzed and Forecasts a New Research Report at Sandlerresearch.org
PRWeb - Thu Jul 17, 4:30AM CDT
In the recent past, vendors have entered into several agreements or partnerships to develop or introduce new products or drugs in the Global Women's Health market. Some of the major acquisitions include Conceptus by Bayer, Warner Chilcott by Actavis, Uteron Pharma by Watson Pharmaceuticals, and Barr Pharmaceuticals by Teva Pharmaceutical. Some of the other prominent collaborations include Bayer with EndoCeutics to develop Vaginorm for treatment of vaginal atrophy, AbbVie with Neurocrine Biosciences to develop and commercialize Elagolix, and all next-generation GnRH antagonists for women's and men's health.
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2014: 16 Companies & 27 Drugs Profiled
M2 - Thu Jun 19, 3:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hhf5zs/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Post-Traumatic Stress Disorder (PTSD) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Post-Traumatic Stress Disorder (PTSD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Post-Traumatic Stress Disorder (PTSD) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Nanotherapeutics, Inc. - Neurocrine Biosciences, Inc. - Addex Therapeutics - Neuralstem, Inc. - Catalyst Pharmaceutical Partners, Inc. - Humanetics Corporation - NeuroNascent, Inc. - Azevan Pharmaceuticals, Inc. - Omeros Corporation - Intra-Cellular Therapies, Inc. - Vanda Pharmaceuticals Inc. - Marinus Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Tonix Pharmaceuticals Holding Corp. - Sage Therapeutics - Istituto Italiano di Tecnologia Drug Profiles - brexpiprazole - PRX-3140 - verucerfont - atorvastatin calcium - aprepitant - ganaxolone - iloperidone - mifepristone - oxytocin - 7-Keto - SRX-251 - SRX-246 - ITI-007 - NNI-351 - mGluR7-NAM Program For Central Nervous System Disorders - NSI-189 - cyclobenzaprine hydrochloride - S-107 - Small Molecule Targeting GABAA Receptor For Post Traumatic Stress Disorder - ZL-006 - ADX-71743 - Dihydroxyflavone - TLR-4 Antagonists for CNS Disorders - Immune Therapy For PTSD and Depression - Small Molecule Targeting GPR83 for CNS and Autoimmune Disorders - Small Molecules to Inhibit FAAH for CNS Disorders - vigabatrin For more information visit http://www.researchandmarkets.com/research/hh...ttraumatic
Neurocrine Biosciences To Present At The 26th Annual Roth Conference
PR Newswire - Tue Mar 04, 1:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 26th Annual Roth Conference in Laguna.
Neurocrine Biosciences To Present At The Cowen And Company 34th Annual Health Care Conference
PR Newswire - Thu Feb 27, 6:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Cowen and Company 34th Annual Health Care Conference in Boston.
Neurocrine Biosciences prices public offering at USD17.75 per share
M2 - Thu Feb 27, 5:17AM CST
US-based drug company Neurocrine Biosciences (NasdaqGS:NBIX) said on Wednesday that it has priced its public offering of 8m shares of its common stock at USD17.75 per share.
Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock
PR Newswire - Wed Feb 26, 8:12PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $17.75 per share. The gross proceeds to Neurocrine from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Neurocrine, are expected to be approximately $142 million. The offering is expected to close on or about March 4, 2014, subject to customary closing conditions. Neurocrine anticipates using the net proceeds from the offering to fund its research and development efforts and for general corporate purposes, including working capital.
Digirad Corporation Reports Fourth Quarter and Year-End Financial Results
GlobeNewswire - Wed Feb 26, 5:00AM CST
Digirad Corporation (Nasdaq
RAD) today reported fourth quarter earnings of $0.8 million, or $0.04 per diluted share, with total revenues of $12.5 million. Ending cash, cash equivalents and available-for-sale securities was $26.4 million.
Neurocrine Biosciences proposes public offering of 7m common shares
M2 - Wed Feb 26, 3:06AM CST
Drug company Neurocrine Biosciences (NasdaqGS:NBIX) said on Tuesday that it plans to sell 7,000,000 shares of its common stock in an underwritten public offering.
Directory of South & Central American Libraries 2013
M2 - Wed Feb 26, 2:23AM CST
This new edition of the Directory of South & Central American Libraries provide essential details on all libraries throughout South and Central America including universities, public and special libraries and including the libraries of institutes and research centres.
Neurocrine Biosciences, Inc. Announces Proposed Public Offering of Common Stock
PR Newswire - Tue Feb 25, 3:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it is offering to sell 7,000,000 shares of its common stock in an underwritten public offering. In connection with this offering, Neurocrine will also grant to the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of common stock. Jefferies LLC and J.P. Morgan Securities LLC are acting as joint book-running managers for this offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
PR Newswire - Wed Sep 03, 12:00PM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Morgan Stanley Global Healthcare Conference in New York City.
The Best Hedge Fund You've Never Heard Of and Its Top 5 Stock Picks
at The Street - Tue Aug 26, 1:22PM CDT
It's not the hedge fund mogul you expect.
Neurocrine Biosciences posts higher net loss of USD13.4m for Q2 2014
M2 - Thu Aug 07, 5:02AM CDT
Drug company Neurocrine Biosciences (NasdaqGS:NBIX) disclosed on Wednesday that its net loss was USD13.4m (USD0.18 loss per share) for the second quarter ended 30 June 2014.
Neurocrine Biosciences Reports Second Quarter 2014 Results
PR Newswire - Wed Aug 06, 3:02PM CDT
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended June 30, 2014. For the second quarter of 2014, the Company reported a net loss of $13.4 million, or $0.18 loss per share, compared to a net loss of $12.2 million, or $0.18 loss per share, for the same period in 2013. For the six months ended June 30, 2014, the Company reported a net loss of $25.2 million, or $0.35 loss per share, as compared to net loss of $24.3 million, or $0.36 loss per share, for the first half of last year.
Global PCOS (Stein-Leventhal Syndrome) Drugs Market 2014-2018
M2 - Wed Aug 06, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gszg6d/global_pcos_drugs) has announced the addition of the "Global PCOS Drugs Market 2014-2018" report to their offering. The analysts forecast the Global PCOS Drugs market will grow at a CAGR of 2.665% over the period 2013-2018. PCOS, also known as Stein-Leventhal Syndrome, is one of the most common hormonal endocrine disorders in women. It is characterized by polycystic ovaries, irregular or no menstrual periods, irregular ovulation, and high levels of androgens (male hormones) in the body. The exact cause of PCOS is unknown. In PCOS, small cysts form on the ovaries, which do not produce a sufficient amount of hormone to initiate ovulation. The ovarian follicles, which are filled with fluid in preparation for ovulation, remain as cysts when ovulation does not occur. Lifestyle modifications, medication, and surgery are some of the currently available treatments for PCOS. This report covers the present scenario and the growth prospects of the Global PCOS Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through the sales of marketed, off-label, and generic drugs used in the treatment of PCOS. The report, the Global PCOS Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global PCOS Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Bristol Myers Squibb Co. - Merck & Co. Inc. - Novartis AG - Sanofi SA - Teva Pharmaceutical Inc. Other Prominent Vendors - AstraZeneca plc - Catalysis SL - Crinetics Pharmaceuticals Inc. - Dexa Medica Group - EffRx Inc. - Neurocrine Biosciences Inc. Market Drivers/Challenges/Trends - Increase in Patient Population. - Lack of Approved Drugs. - Increase in Awareness of PCOS Drugs. Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. For more information visit http://www.researchandmarkets.com/research/gs...pcos_drugs
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences
PR Newswire - Thu Jul 31, 7:40AM CDT
On Wednesday, July 30, 2014, the NASDAQ Composite ended at 4,462.90, up 0.45%, the Dow Jones Industrial Average finished the day 0.19% lower at 16,880.36, and the S&P 500 closed at 1,970.07, up 0.01%. During the session five out of ten sectors ended in positive. The S&P 500 Health Care Sector Index ended the day at 718.94, up 0.36%, and the index has advanced 2.05% in the last one month. Investor-Edge has initiated coverage on the following equities: IsoRay Inc. (NYSE MKT: ISR), Neurocrine Biosciences Inc. (NASDAQ: NBIX), OPKO Health Inc. (NYSE: OPK), Orexigen Therapeutics Inc. (NASDAQ: OREX), and Gilead Sciences Inc. (NASDAQ: GILD). Free research on these five companies can be accessed at:
Critical Alerts For Silicon Motion Technology, Pharmacyclics, 3D Systems, Walgreen, and Neurocrine Biosciences Released By InvestorsObserver
PR Newswire - Wed Jul 30, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for SIMO, PCYC, DDD, WAG, and NBIX.
Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results
PR Newswire - Tue Jul 29, 9:00AM CDT
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its second quarter 2014 financial results after the Nasdaq market closes on Wednesday, August 6, 2014. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Thursday morning, August 7, 2014 at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time).
Global Insomnia Clinical Trials Review, H2, 2014 Featuring 10 Companies & 10 Institutes
M2 - Thu Jul 17, 8:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xplssq/insomnia_global) has announced the addition of the "Insomnia Global Clinical Trials Review, H2, 2014" report to their offering. Insomnia Global Clinical Trials Review, H2, 2014" provides data on the Insomnia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Insomnia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Insomnia. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Takeda Pharmaceutical Company Limited - Merck & Co., Inc. - Dainippon Sumitomo Pharma Co., Ltd. - Sanofi - Neurocrine Biosciences, Inc. - Pfizer Inc. - GlaxoSmithKline plc - Neurim Pharmaceuticals Ltd - Eisai Co., Ltd. - Actelion Ltd Clinical Trial Overview of Top Institutes / Government - University of Rochester - Duke University - U.S. Department of Veterans Affairs - Karolinska Institute - University of Pittsburgh - Brigham and Women's Hospital - Stanford University - The University of Hong Kong - Massachusetts General Hospital - National Institute of Mental Health For more information visit http://www.researchandmarkets.com/research/xp...nia_global
Women Health Market Growth Prospects for 2014 to 2018 Analyzed and Forecasts a New Research Report at Sandlerresearch.org
PRWeb - Thu Jul 17, 4:30AM CDT
In the recent past, vendors have entered into several agreements or partnerships to develop or introduce new products or drugs in the Global Women's Health market. Some of the major acquisitions include Conceptus by Bayer, Warner Chilcott by Actavis, Uteron Pharma by Watson Pharmaceuticals, and Barr Pharmaceuticals by Teva Pharmaceutical. Some of the other prominent collaborations include Bayer with EndoCeutics to develop Vaginorm for treatment of vaginal atrophy, AbbVie with Neurocrine Biosciences to develop and commercialize Elagolix, and all next-generation GnRH antagonists for women's and men's health.
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2014: 16 Companies & 27 Drugs Profiled
M2 - Thu Jun 19, 3:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hhf5zs/posttraumatic) has announced the addition of the "Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Post-Traumatic Stress Disorder (PTSD) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Post-Traumatic Stress Disorder (PTSD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Post-Traumatic Stress Disorder (PTSD) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Nanotherapeutics, Inc. - Neurocrine Biosciences, Inc. - Addex Therapeutics - Neuralstem, Inc. - Catalyst Pharmaceutical Partners, Inc. - Humanetics Corporation - NeuroNascent, Inc. - Azevan Pharmaceuticals, Inc. - Omeros Corporation - Intra-Cellular Therapies, Inc. - Vanda Pharmaceuticals Inc. - Marinus Pharmaceuticals, Inc. - Otsuka Holdings Co., Ltd. - Tonix Pharmaceuticals Holding Corp. - Sage Therapeutics - Istituto Italiano di Tecnologia Drug Profiles - brexpiprazole - PRX-3140 - verucerfont - atorvastatin calcium - aprepitant - ganaxolone - iloperidone - mifepristone - oxytocin - 7-Keto - SRX-251 - SRX-246 - ITI-007 - NNI-351 - mGluR7-NAM Program For Central Nervous System Disorders - NSI-189 - cyclobenzaprine hydrochloride - S-107 - Small Molecule Targeting GABAA Receptor For Post Traumatic Stress Disorder - ZL-006 - ADX-71743 - Dihydroxyflavone - TLR-4 Antagonists for CNS Disorders - Immune Therapy For PTSD and Depression - Small Molecule Targeting GPR83 for CNS and Autoimmune Disorders - Small Molecules to Inhibit FAAH for CNS Disorders - vigabatrin For more information visit http://www.researchandmarkets.com/research/hh...ttraumatic
Neurocrine Biosciences To Present At The 26th Annual Roth Conference
PR Newswire - Tue Mar 04, 1:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 26th Annual Roth Conference in Laguna.
Neurocrine Biosciences To Present At The Cowen And Company 34th Annual Health Care Conference
PR Newswire - Thu Feb 27, 6:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Cowen and Company 34th Annual Health Care Conference in Boston.
Neurocrine Biosciences prices public offering at USD17.75 per share
M2 - Thu Feb 27, 5:17AM CST
US-based drug company Neurocrine Biosciences (NasdaqGS:NBIX) said on Wednesday that it has priced its public offering of 8m shares of its common stock at USD17.75 per share.
Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock
PR Newswire - Wed Feb 26, 8:12PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $17.75 per share. The gross proceeds to Neurocrine from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Neurocrine, are expected to be approximately $142 million. The offering is expected to close on or about March 4, 2014, subject to customary closing conditions. Neurocrine anticipates using the net proceeds from the offering to fund its research and development efforts and for general corporate purposes, including working capital.
Digirad Corporation Reports Fourth Quarter and Year-End Financial Results
GlobeNewswire - Wed Feb 26, 5:00AM CST
Digirad Corporation (Nasdaq
RAD) today reported fourth quarter earnings of $0.8 million, or $0.04 per diluted share, with total revenues of $12.5 million. Ending cash, cash equivalents and available-for-sale securities was $26.4 million. Neurocrine Biosciences proposes public offering of 7m common shares
M2 - Wed Feb 26, 3:06AM CST
Drug company Neurocrine Biosciences (NasdaqGS:NBIX) said on Tuesday that it plans to sell 7,000,000 shares of its common stock in an underwritten public offering.
Directory of South & Central American Libraries 2013
M2 - Wed Feb 26, 2:23AM CST
This new edition of the Directory of South & Central American Libraries provide essential details on all libraries throughout South and Central America including universities, public and special libraries and including the libraries of institutes and research centres.
Neurocrine Biosciences, Inc. Announces Proposed Public Offering of Common Stock
PR Newswire - Tue Feb 25, 3:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it is offering to sell 7,000,000 shares of its common stock in an underwritten public offering. In connection with this offering, Neurocrine will also grant to the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of common stock. Jefferies LLC and J.P. Morgan Securities LLC are acting as joint book-running managers for this offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
